только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 3 / 4
Страница 1 / 1

Литература

  1. Бехтерева Н. П., Камбарова Д. К., Поздеев В. К. Устойчивое патологическое состояние при болезнях мозга. М.: Медицина, 1978. 240 с.
  2. Большая медицинская энциклопедия. Том 1 / глав. ред. Б. В. Петровский. М., 1974. 576 с.
  3. Гасанов Р. Ф. К вопросу о когнитивном развитии детей с гиперкинетическим расстройством // Неврологический вестник. 2015; 47 (3): 25–29.
  4. Гасанов Р. Ф. Современные представления об этиологии синдрома дефицита внимания // Обозрение психиатрии и медицинского психологии имени В. М. Бехтерева. 2010; 1: 4–10.
  5. Гасанов Р. Ф. Формирование представления о синдроме дефицита внимания у детей. СПб.: СПб НИПНИ им. В. М. Бехтерева, 2009. 174 с.
  6. Глущенко В. В. Предварительные результаты сравнительного анализа психофармакотерапии при синдроме дефицита внимания с гиперактивностью // Вестник Новгородского государственного университета имени Ярослава Мудрого. 2010; 59: 9–11.
  7. Громова Е. А. Функциональные взаимоотношения катехоламинергической и серотонинергической систем мозга — антагонизм или реципрокность? // Катехоламинергические нейроны / под ред. Т. М. Турпаева, А. Ю. Буданцева. М.: Наука, 1976: 97–105.
  8. Курский М. Д., Бакшеев Н. С. Биохимические основы механизма действия серотонина. Киев: Наукова думка, 1974. 112 с.
  9. Лаврентьева Г. П., Титаренко Т. М. Практическая психология для воспитателя. Киев, 1992.
  10. Мальцева Л. А., Саланжий А. Н. Механизмы формирования стресса у врачей-анестезиологов соответственно стажу работы по специальности // Медицина неотложных состояний. 2013; 6 (53): 63–66.
  11. Микадзе Ю. В. Нейропсихологический анализ формирования психических функций у детей // Сб. докладов 1 Международной конференции памяти А. Р. Лурия. М., 1998: 225–231.
  12. Павличенко А. В. Клинические особенности применения миртазапина (миртазонала) // Эффективная фармакотерапия в неврологии и психиатрии. 2010; 3: 16–20.
  13. Редько А. В. Изменение активности ферментов, катализирующих окислительно-восстановительные превращения альдегидов, в тканях крыс пубертатного возраста при стрессе // Експериментальна і клінічна медицина. 2009; 3: 28–31.
  14. Узбеков М. Г. Гиперкинетический синдром как проявление нарушений развития моноаминергических систем головного мозга // Социальная и клиническая психиатрия. 2006; 16 (2): 31–44.
  15. Узбеков М. Г. Нейрохимические аспекты взаимосвязи моноаминергических и гормональной систем в патогенезе тревожной депрессии // Социальная и клиническая психиатрия. 2005; 2: 108–110.
  16. Утевский А. М., Расин М. С. Катехоламины и кортикостероиды (молекулярные аспекты взаимоотношений двух основных адаптационных систем) // Успехи совр. биол. 1972; 3: 323–341.
  17. Чутко Л. С., Айкбеков К. А., Лапшина О. В. и др. Коморбидные тревожные расстройства при синдроме дефицита внимания с гиперактивностью // Журнал неврологии и психиатрии им. С. С. Корсакова. 2008; 108 (3): 34–39.
  18. Чутко Л. С., Пальчик А. Б., Кропотов Ю. Д. Синдром нарушения внимания с гиперактивностью у детей и подростков. СПб.: СПбМАПО, 2004. 112 с.
  19. Чутко Л. С., Сурушкина С. Ю., Никишена И. С. и др. Астения у подростков с синдромом дефицита внимания и их лечение нооклерином // Журнал неврологии и психиатрии им. С. С. Корсакова. Спецвыпуски. 2015; 115 (52): 42–45.
  20. Энциклопедия клинических лабораторных тестов. М.: ЮНИМЕД-пресс, 2003. 960 с.
  21. Яременко Б. Р., Яременко А. Б., Горяинова Т. Б. Минимальные дисфункции головного мозга у детей. СПб.: Салт-Медкнига, 2002. 129 с.
  22. Arda E., Cakiroglu B., Thomas D. T. Primary Nocturnal Enuresis: A Review // Nephro-Urol. Mon. 2016; 8 (4): e35809.
  23. Baeyens D., Roeyers H., Demeyere I. et al. Attentiondeficit/hyperactivity disorder (ADHD) as a risk factor for difficult to cure nocturnal enuresis in children: A two-year follow-up study // Acta Paediatrica. 2005; 94: 1619.
  24. Baeyens D., Roeyers H., D’Hase L. et al. The prevalence of ADHD in children with enuresis: Comparison between samples of primary care and pediatric clinic // Acta Paediatrica. 2006; 95: 347–352.
  25. Baker G. B., Bornstein R. A., Douglass A. B. et al. Urinary excretion of metabolites of norepinephrine in Tourette’s syndrome // Mol. Chem. Neuropathol. 1990; 13 (3): 225–232.
  26. Bansal A. S. Investigating unexplained fatigue in general practice with a particular focus on CFS/ME // BMC Fam. Pract. 2016; 17: 81.
  27. Barkley R. A., Fischer M., Smallish L., Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities // Journal of the American Academy of Child and Adolescent Psychiatry. 2006; 45 (2): 192–202.
  28. Biederman J., Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder // Biol. Psychiatry. 1999; 46: 1234–1242.
  29. Cakiroglu B., Tas T., Eyyupoglu S. E. et al. The adverse influence of spina bifida occulta on the medical treatment outcome of primary monosymptomatic nocturnal enuresis // Arch. Ital. Urol. Androl. 2014; 86 (4): 270–273.
  30. Carmona S., Vilarroya O., Bielsa A. et al. Global and regional gray matter reductions in ADHD: a voxel-based morphometric study // Neurosci. Lett. 2005; 389: 88–93.
  31. Casimiri V., Cohen W. R., Parvez S. et al. Phenylethanolamine-N-methyl transferase and catechol-O-methyltransferase activity in rat uterus. Cyclic and steroid-induced changes // Acta Obstet. Gynecol. Scand. 1993; 72: 606–610.
  32. Castellanos F. X., Giedd J. N., Eckburg P. et al. Quantitative morphology of the caudate nucleus in attention deficit hyperactivity disorder // Am. J. Psychiatry. 1994; 151: 1791–1796.
  33. Castellanos F. X., Rapoport J. L. Etiology of attention deficit hyperactivity disorder // Child Adolesc. Psychiat. Clin. N. Am. 1992; 1: 373–384.
  34. Castellanos F. X., Sharp W. S., Gottesman R. F. et al. Anatomic brain abnormalities in monozygotic twins discordant for attention deficit hyperactivity disorder // Am. J. Psychiatry. 2003; 160: 1693–1696.
  35. Chang J. W., Yang L. Y., Chin T. W. et al. Clinical characteristics, nocturnal antidiuretic hormone levels, and responsiveness to DDAVP of school children with primary nocturnal enuresis // World J. Urol. 2012; 30 (4): 567–571.
  36. Comings D. E. Clinical and Molecular Genetics of ADHD and Tourette Syndrome: Two Related Polygenic Disorders // Ann. N. Y. Acad. Sci. 2001; 931: 50–83.
  37. Diagnostic and Statistical of Mental Disorders. 4th еd. Washington, 1994.
  38. Diamond A. Executive Functions // Annual Review of Psychology. 2013; 64 (1): 135–168.
  39. Donfrancesco R., Di Trani M., Gregori P. et al. Attention-deficit/hyperactivity disorder and alexithymia: a pilot study // Atten. Defic. Hyperact. Disord. 2013; 5 (4) 361–367.
  40. Dynarowicz I., Paprocki M. The activity of catechol-O-methyltransferase and monoamine oxidase in the uterine artery of pigs during the oestrous cycle // Arch. Vet. Pol. 1993; 33: 39–45.
  41. Engle R. W. Working Memory Capacity as Executive Attention // Current Directions in Psychological Science. 2002; 11 (1): 19–23.
  42. Estévez-López F., Mudie K., Wang-Steverding X. et al. Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology // J. Clin. Med. 2020; 9 (5): 1557.
  43. Feehan M., McGee R., Stanton W. 6 year follow-up of childhood enuresis: prevalence in adolescence and consequences for mental health // J. Paediatr. Child Health. 2019; 26 (2): 75–79.
  44. Fernstrom J. D. Effects of the diet on brain neurotransmitters // Metabolism. 1977; 26 (2): 207–223.
  45. Garvey M. J., Noyes R. J., Woodman C. et al. Relationship of generalized anxiety symptoms to urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid // Psychiatry Res. 1995; 57 (1): 1–5.
  46. Garvey M. J., Noyes R. J., Woodman C. et al. The association of urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid in patients with generalized anxiety // Neuropsychobiology. 1995; 31 (1): 6–9.
  47. Genizi J., Gordon S., Kerem N. C. et al. Primary headaches, attention deficit disorder and learning disabilities in children and adolescents // J. Headache Pain. 2013; 14: 54.
  48. Green A. R., Curzon G. Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol // Nature. 1968; 220 (5172): 1095–1097.
  49. Greimel E., Wanderer S., Rothenberger A. et al. Attentional performance in children and adolescents with tic disorder and co-occurring attention-deficit/hyperactivity disorder: new insights from a 2×2 factorial design study // J. Abnorm. Child Psychol. 2011; 39: 819–828.
  50. Hershey A. D., Powers S. W., Winner P., Kabbouche M. A. Pediatric Headaches in Clinical Practice. London: Wiley-Blackwell, 2009. 223 p.
  51. Hill A., Volpe J. J. Ischemic and Haemorrhagic Lesions of Newborn // Cerebrovascular Diseases in Children / ed. by A. J. Reimondi, M. Choux, C. Di Rocco. Stuttgart; New York: Spring Verlag., 1992: 206–215.
  52. Jackson G., Mueller S., Hambleton K., Hollis C. Enhanced cognitive control in Tourette Syndrome during task uncertainty // Experimental Brain Research. 2007; 182 (3): 357–364.
  53. Koh M., Noh E. A., Kim H. W. Korean Wechsler Intelligence Scale for children-fourth edition profiles in child and adolescent with attention deficit hyperactivity disorder: retrospective study // J. Korean Acad. Child Adolesc. Psychiatry. 2015; 26: 183–189.
  54. Krageloh-Mann I., Toft P., Lunding J. et al. Brain lesions in preterms: origin, consequences and compensation // Acta Pediatrica. 1999; 88: 897–908.
  55. Krain A. L., Castellanos F. X. Brain development and ADHD // Clin. Psychol. Rev. 2006; 26 (4): 433–444.
  56. Leckman J. F., Riddle M. A., Hardin M. T. et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity // J. Am. Acad. Child Adolesc. Psychiatry. 1989; 28 (4): 566–573.
  57. Leckman J. F., Vaccarino F. M., Kalanithi P. S., Rothenberger A. Annotation: Tourette syndrome: a relentless drumbeat — driven by misguided brain oscillations // Journal of Child Psychology and Psychiatry. 2006; 47 (6): 537–550.
  58. Lim E. J., Ahn Y. C., Jang E. S. et al. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) // J. Transl. Med. 2020; 18: 100.
  59. Maas J. W., Leckman J. F. Relationship between central nervous system noradrenergic function and plasma urinary MHPG // MHPG: Basic mechanisms in psychopharmacology / ed. by J. W. Maas. New York: Academic Press, 1983: 33–44.
  60. Mahone E. M., Cirino P. T., Cutting L. E. et al. Validity of the behavior rating inventory of executive function in children with ADHD and/or Tourette syndrome // Arch. Clin. Neuropsychol. 2002; 17: 643–662.
  61. Maksoud R., du Preez S., Eaton-Fitch N. et al. A systematic review of neurological impairments in myalgic encephalomyelitis / chronic fatigue syndrome using neuroimaging techniques // PLoS ONE. 2020; 15 (4): e0232475.
  62. Mancini C., Van Ameringen M., Oakman J. M., Figueiredo D. Childhood attention deficit/ hyperactivity disorder in adults with anxiety disorders // Psychol. Med. 1999; 29 (3): 515–525.
  63. Matier K., Halperin J. M., Sharma V. et al. Methylphenidate response in aggressive and nonaggressive ADHD children: distinctions on laboratory measures of symptoms // J. Am. Acad. Child Adolesc. Psychiatry. 1992; 31 (2): 219–225.
  64. Maura G., Gemignani A., Raiteri M. Noradrenaline inhibits central serotonin release through alpha 2-adrenoceptors located on serotonergic nerve terminals // Naunyn Schmiedebergs Arch. Pharmacol. 1982; 320 (3): 272–274.
  65. Max J. E., Manes F. F., Robertson B. A. et al. Prefrontal and executive attention network lesions and the development of attention-deficit/hyperactivity symptomatology // J. Am. Acad. Child Adolesc. Psychiatry. 2005; 44: 443–450.
  66. Mogg K., Salum G. A., Bradley B. P. et al. Attention network functioning in children with anxiety disorders, attention-deficit/hyperactivity disorder and non-clinical anxiety // Psychological Medicine. 2015; 45 (12): 2633–2646.
  67. Nelson K. B., Ellenberg J. H. Apgar scores as predictors of chronic neurologic disability // Pediatrics. 1981; 68: 36–44.
  68. Nemeth S. The effect of stress or glucose feeding on hepatic tyrosine aminotransferase activity and liver and plasma tyro-sine levels of intact and adrenalectomized rats // Horm. metab. Res. 1978; 10: 144–147.
  69. Nigg G. T. What causes ADHD? New York, London: The Guilford Press, 2006. 422 р.
  70. Nisbett R. E., Aronson J., Blair C. et al. Intelligence. New Findings and Theoretical Developments // American Psychologist. 2012; 67 (2): 130–159.
  71. Nutt D., Ballenger J. Anxiety Disorders. Wiley-Blackwell, 2005.
  72. Oades R. D. Dopamine may be «hyper» with respect to noradrenaline metabolism, but «hypo» with respect to serotonin metabolism in children with attention-deficit hyperactivity disorder // Behav. Brain Res. 2002; 130 (1–2): 97–102.
  73. Oades R. D. The role of norepinephrine and serotonin in ADHD // Attention Deficit Hyperactivity Disorder: From Genes to Animal Models to Patients / ed. by D. Gozal, D. L. Molfese. Totowa, New Jersey: Humana Press, 2005: 97–130.
  74. Oades R. D., Lasky-Su J., Christiansen H. et al. The influence of serotonin- and other genes on impulsive behavioral aggression and cognitive impulsivity in children with attention-deficit/ hyperactivity disorder (ADHD): Findings from a family-based association test (FBAT) analysis // Behavioral and Brain Functions. 2008; 4: 48.
  75. Pennington B. F. Diagnosing Learning Disorders. A Neuropsychological Framework. New York, London, 2009. 355 р.
  76. Petersen S. E., Posner M. I. The attention system of the human brain: 20 years after // Annu. Rev. Neurosci. 2012; 35: 73–89.
  77. Piero A. Personality correlates of impulsivity in subjects. with generalized anxiety disorders // Comprehen. Psych. 2010; 51: 538–545.
  78. Pliszka S. R., McCracken J. T., Maas J. W. Catecholamines in attention deficit hyperactivity disorder: current perspectives // J. Am. Acad. Child Adolesc. Psychiatry. 1996; 35 (3): 264–272.
  79. Preve M., Mula M., Maltini E., Pini S. Panic-agoraphobic spectrum symptoms are associated with impulsivity in bipolar disorder // Ann. Depress. Anxiety. 2014; 1: 1016.
  80. Renna M. E., Seeley S. H., Heimberg R. G. et al. Increased Attention Regulation from Emotion Regulation Therapy for Generalized Anxiety Disorder // Cogn. Ther. Res. 2018; 42: 121–134.
  81. Rothenberger A., Roessner V., Banaschewski T., Leckman J. F. Co-existence of tic disorders and attention-deficit/hyperactivity disorder-recent advances in understanding and treatment // Eur. Child. Adolesc. Psychiatry. 2007; 16 (Suppl 1): 1–4.
  82. Russell V. A. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder — the spontaneously hypertensive rat // Behav. Brain Res. 2002; 130 (1–2): 191–196.
  83. Sandberg S. Hyperkinetic or attention deficit disorder // Br. J. Psychiatry. 1996; 169: 10–17.
  84. Seidman L. J., Valera E. M., Makris N. Structural brain imaging of attention-defcit/hyperactivity disorder // Biol. Psychiatry. 2005; 57: 1263–1272.
  85. Serrien D. J. Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation pattern as revealed by EEG coherence // Brain. 2004; 128 (10): 116–125.
  86. Schröder A., Vulink N., Denys D. Misophonia: Diagnostic Criteria for a New Psychiatric Disorder // PLoS ONE. 2013; 8 (1): e54706.
  87. Schuerholz L. J., Baumgarder T. L., Singer H. S. et al. Neuropsychological status of children with Tourette’s syndrome with and without attention deficit hyperactivity disorders // Neurology. 1996; 46 (4): 958–965.
  88. Shaywitz S. E., Cohen D. J., Shaywitz B. A. The biochemical basis of minimal brain dysfunction // J Pediat. 1978; 92: 179–187.
  89. Shekim W. O., Javaid J., Dans J. M., Bylund D. B. M. Urinary MHPG and HVA excretion in boys with attention deficit disorder and hyperactivity treated with d-amphetamine // Biol. Psychiatry. 1983; 18: 707–714.
  90. Sokol M. S., Campbell M., Goldstein M., Kriechman A. M. Attention deficit disorder with hyperactivity and the dopamine hypothesis: case presentations with theoretical background // J. Am. Acad. Child Adolesc. Psychiatry. 1987; 26: 428–433.
  91. Steeves T. D., Ko J. H., Kideckel D. M. et al. Extrastriatal dopaminergic dysfunction in Tourette syndrome // Ann. Neurol. 2010; 67 (2): 170–181.
  92. Stovner L., Hagen K., Jensen R. et al. The Global Burden of Headache: A Documentation of Headache Prevalence and Disability Worldwide // Cephalalgia. 2007; 27: 193–210.
  93. Sukhodolsky D. G., Landeros-Weisenberger A., Scahill L. et al. Neuropsychological functioning in children with Tourette syndrome with and without attention-deficit/hyperactivity disorder // J. Am. Acad. Child Adolesc. Psychiatry. 2010; 49: 1155–1164.
  94. Swann A., Pazzaglia P., Nicholls A. et al. Impulsivity and phase of illness in bipolar disorder // J. Affect. Disord. 2003; 73: 105–111.
  95. Swanson J. M. School-based assessments and interventions for ADD students. Irvine: KC Publishing, 1992. 184 p.
  96. Taylor C. T., Hirshfeldt-Becker D. R., Ostacher M. J. et al. Anxiety is associated with impulsivity in bipolar disorder // J. Anxiety Disord. 2008; 22: 868–876.
  97. Textbook of Clinical Chemistry and Molecular Diagnostics. 4 ed. New Delhi: Elsevier, 2006. 2412 p.
  98. The International Classification of Headache Disorders (ICHD-3). 3rd ed. // Cephalalgia. 2018; 38 (1): 1–211.
  99. Toga A. W., Thompson P. M., Sowell E. R. Mapping brain maturation // Trends Neurosci. 2006; 29: 148–159.
  100. Van Herzeele C., De Bruyne P., De Bruyne E., Walle J. V. Challenging factors for enuresis treatment: psychological problems and nonadherence // J. Pediatr. Urol. 2015; 11 (6): 308–313.
  101. Von Gontard A., Equit M. Comorbidity of ADHD and incontinence in children // Eur. Child Adolesc. Psychiatry. 2015; 24 (2): 127–140.
  102. Von Gontard A., Moritz A. M., Thome-Granz S. et al. Association of attention deficit and elimination disorders at school entry — a population-based study // Journal of Urology. 2011; 186: 2027–2032.
  103. Wong D. F., Brasic J. R., Singer H. S. et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET // Neuropsychopharmacology. 2008; 33 (6): 1239–1251.
  104. Yang Y., Zhang X., Zhu Y. et al. Cognitive impairment in generalized anxiety disorder revealed by event-related potential N270 [J] // Neuropsychiatr. Dis. Treat. 2015; 11: 1405–1411.
  105. Yüce M., Zoroglu S., Ceylan F. et al. Psychiatric comorbidity distribution and diversities in children and adolescents with attention deficit/hyperactivity disorder: a study from Turkey // Neuropsychiatr. Dis. Treat. 2013; 9: 1791–1799.
  106. Zald D. H., Cowan R. L., Riccardi P. et al. Midbrain dopamine receptor availability is inversely associated with novelty-seeking traits in humans // J. Neurosci. 2008; 28: 14372–14378.
  107. Zametkin A. J., Rapoport J. L. Noradrenergic hypothesis of attention deficit disorder with hyperactivity: a critical review // Psychopharmacology: The Third Generation of Progress / ed. by H. Y. Meltzer. New York: Raven, 1987: 837–842.
  108. Zwart J. A., Dyb G., Holmen T. L. et al. The prevalence of migraine and tension-type headaches among adolescents in Norway. The Nord-Trondelag Health Study (Head-HUNT-Youth), a large population-based epidemiological study // Cephalalgia. 2004; 24: 373–379.